BioSpace News Archive

PDS Biotechnology Corporation (Nasdaq: PDSB), today announced that its independent Data Monitoring Committee (DMC) met for its scheduled review of PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for the potential treatment of recurrent or metastatic HPV16-positive head and neck cancer.

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics, will present at the H.C. Wainwright 2nd Annual Ophthalmology Conference.

LenioBio GmbH, the German life science biotech offering a disruptive protein manufacturing technology, today announced the appointment of Mr. Jasper Levink to its Leadership Team in the role of Chief Business Officer.

Endologix LLC , a privately held global medical device company dedicated to improving patients’ lives with innovative interventional treatments for vascular disease, announced that is has received CE Mark Certification under the new EU Medical Devices Regulation [EU-MDR [(Regulation (EU) 2017/745)] for its AFX2 Endovascular AAA System.

Lineage Cell Therapeutics, Inc. today announced that it will report its second quarter 2022 financial and operating results on Thursday, August 11, 2022, following the close of the U.S. financial markets.

Immune Therapeutics, Inc., a specialty pharmaceutical company involved in the acquisition, development, and commercialization of pharmaceutical and biotechnology products that have a short and well-defined path to market, is pleased to announce the appointment of Glen Farmer as Chief Financial Officer and Kelly Wilson as Chief Operating Officer.

An estimated 2.5 million people suffer Traumatic Brain Injuries annually in the United States with children, young adults and senior citizens being the most vulnerable.

PROCEPT® BioRobotics Corporation, a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, reported unaudited financial results for the quarter ended June 30, 2022.

CymaBay Therapeutics, Inc. announced that it will host a conference call and live audio webcast on Thursday, August 11, 2022 at 4:30 p.m. Eastern Time to discuss financial results for the second quarter ended June 30, 2022 and to provide a business update.

Apellis Pharmaceuticals, Inc. announced that the company approved the grant of equity awards to two new employees with a grant date of August 1, 2022, as equity inducement awards outside of the company’s 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.